Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Applied Therapeutics Inc APLT

Healthcare Biotechnology
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.


NDAQ:APLT - Post by User

Applied Therapeutics Inc
<< Previous
 Bullboard Posts
User Avatar Image
(291)
•••
Post by whytestockson Dec 20, 2024 6:30pm
22 Views
Post# 36373093

APLT COURT REMINDER: Applied Therapeutics, Inc. Investors th

APLT COURT REMINDER: Applied Therapeutics, Inc. Investors th
News; $APLT APLT COURT REMINDER: Applied Therapeutics, Inc. Investors that Lost Money when Stock Plummeted 80% are Encouraged to Contact BFA Law (NASDAQ:APLT)NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Leading securities law firm Bleichmar Fonti &amp; Auld LLP announces that a lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ:APLT) and certain of the Company's senior executives for potential violations of the federal securitie...APLT - APLT COURT REMINDER: Applied Therapeutics, Inc. Investors that Lost Money when Stock Plummeted 80% are Encouraged to Contact BFA Law (NASDAQ:APLT)

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities